      |
|
||||||||
|
Dr. Irma Joosten
Research interests include immunology and immunogenetics, with a specific focus on delineating processes that underlie immunological tolerance, especially in transplantation. Regulatory T cells, Natural Killer cells and the role of non-classical HLA antigens in the regulation of allo-responses are among the currently studied topics. The development of diagnostic tools and definition of biomarkers to monitor immunological tolerance is an ongoing area of interest. Current projects also include the clinical use of regulatory T cells and NK cells for immunotherapy. |
||||||||
|
Recent key publications Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008 Sep 15;112(6):2340-52. Epub 2008 Jul 10. 2.: Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I, Long EO. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 2006 Jan;4(1):e9. 3: Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood. 2006 Feb 1;107(3):1018-23. Epub 2005 Oct 6. 4: Kreijveld E, Koenen HJ, Hilbrands LB, van Hooff HJ, Joosten I. The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+ CD25- T cells. Blood. 2007 Jan 1;109(1):244-52. Epub 2006 Aug 10. 5: Peters JH, Hilbrands LB, Koenen HJ, Joosten I. Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy. PLoS ONE. 2008 May 21;3(5):e2233. |
||||||||
